| Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention LM Butler, Y Perone, J Dehairs, LE Lupien, V de Laat, A Talebi, M Loda, ... Advanced drug delivery reviews 159, 245-293, 2020 | 366 | 2020 |
| Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer DK Patten, G Corleone, B Győrffy, Y Perone, N Slaven, I Barozzi, E Erdős, ... Nature Medicine 24 (9), 1469-1480, 2018 | 120 | 2018 |
| Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation RS Auriemma, Y Perone, A Di Sarno, LFS Grasso, E Guerra, M Gasperi, ... The Journal of Clinical Endocrinology & Metabolism 98 (1), 372-379, 2013 | 109 | 2013 |
| Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer L Magnani, G Frige, RM Gadaleta, G Corleone, S Fabris, H Kempe, ... Nature genetics 49 (3), 444-450, 2017 | 99 | 2017 |
| Effect of cabergoline on metabolism in prolactinomas RS Auriemma, L Granieri, M Galdiero, C Simeoli, Y Perone, P Vitale, ... Neuroendocrinology 98 (4), 299-310, 2014 | 80 | 2014 |
| Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas RS Auriemma, R Pivonello, Y Perone, LFS Grasso, L Ferreri, C Simeoli, ... European journal of endocrinology 169 (3), 359-366, 2013 | 75 | 2013 |
| SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer Y Perone, AJ Farrugia, A Rodríguez-Meira, B Győrffy, C Ion, A Uggetti, ... Nature communications 10 (1), 2115, 2019 | 51 | 2019 |
| The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 46 | 2021 |
| Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias RS Auriemma, R Pivonello, MC De Martino, G Cudemo, LFS Grasso, ... European journal of endocrinology 168 (1), 15-22, 2013 | 35 | 2013 |
| COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry L Garrigós, C Saura, C Martinez-Vila, A Zambelli, M Bower, B Pistilli, ... Therapeutic Advances in Medical Oncology 13, 17588359211053416, 2021 | 9 | 2021 |
| Going off the grid: ERα breast cancer beyond estradiol Y Perone, L Magnani J. Mol. Endocrinol. 57, F1-F5, 2016 | 4 | 2016 |
| Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer Y Perone, AJ Farrugia, A Rodríguez-Meira, B Győrffy, C Ion, A Uggetti, ... Nature Communications 10, 2019 | 1 | 2019 |
| Journal club: epigenetic profiling to classify cancer of unknown primary Y Perone, FM Fioretti The Lancet Oncology 18 (3), e130, 2017 | 1 | 2017 |
| Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study S De Souza, J Kahol de Jong, Y Perone, S Shetty, M Qurashi, ... Cancers 15 (13), 3378, 2023 | | 2023 |
| Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study. Cancers 2023, 15, 3378 S De Souza, J Kahol de Jong, Y Perone, S Shetty, M Qurashi, ... | | 2023 |
| Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma S De Souza, J Kahol de Jong, Y Perone, S Shetty, M Qurashi, ... | | 2023 |
| Impact of COVID19 on clinical outcomes in hepatocellular carcinoma: A multicentre cohort study S De Souza, JK de Long, Y Perone, S Shetty, M Qurashi, R Jones, V Yip, ... | | 2022 |
| The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma C Fulgenzi, A Muhammed, S Dharmapuri, M Pinter, L Balcar, B Scheiner, ... Journal of Hepatology 77, S372-S373, 2022 | | 2022 |
| Abstract P4-07-06: Breast cancer subtype classification using NanoString and RNAseq technologies A Rocca, S Ravaioli, E Fonzi, I Barozzi, Y Perone, L Magnani, F Pirini, ... Cancer Research 80 (4_Supplement), P4-07-06-P4-07-06, 2020 | | 2020 |
| OR34-2 SREBP1 Drives KRT80-Dependent Cytoskeletal Changes and Invasive Behaviour in Endocrine-Resistant ERα Breast Cancer Y Perone, A Rodríguez Meira, A Farruggia, B Győrffy, C Ion, G Pruneri, ... Journal of the Endocrine Society 3 (Supplement_1), OR34-2, 2019 | | 2019 |
